期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

双膦酸盐类药物相关颌研究进展 被引量：1

下载PDF
导出
摘要 恶性肿瘤转移常发生于骨组织,恶性肿瘤的骨转移可导致大量并发症,这些并发症主要包括高钙血症、疼痛、脊髓压迫、病理性骨折等骨相关事件[1],在此种疾病的治疗方法中,双膦酸盐类药物(Bisphosphonates,Bps)无疑是药物中的最优选择[2]。双膦酸盐类药物相关颌骨坏死(BisphosphonateRelated Osteonecrosis of the Jaw,BRONJ)是使用Bps的一种严重副反应,发生率高低不等,最高可达28%,非常影响患者的生活质量。研究表明,此类患者的治疗措施因患者病情的严重程度不同而存在差异,从外科干预到抗生素和镇痛药的管理,已经提出了各种治疗方案[3],但这些方案多以减轻患者疼痛、控制组织感染、减慢或终止骨坏死的进程为主[4]。本文就药物相关性颌骨坏死的相关发病机制、分期以及治疗方法作一综述。
作者 夏青
机构地区 贵州医科大学
出处 《全科口腔医学电子杂志》 2018年第32期24-24,38,共2页 Electronic Journal of General Stomatology
关键词 双膦酸盐类药物 颌骨坏死 治疗
分类号 R782 [医药卫生—口腔医学]
  • 相关文献

参考文献1

二级参考文献28

  • 1Smith MR, Saad F, Coleman R, et al. Denosumab and bone- metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 2012, 379(9810): 39-46.
  • 2Ruggiero SL, Dodson TB, Famasia 5, et aL American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg, 2014,72(10): 1938-1956.
  • 3Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ, 2003, 327(7413): 469.
  • 4Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer, 2008, 113(6): 1438-1445.
  • 5Fusco V, Bedogni A, Campisi G. Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab. Support Care Cancer, 2014, 22 (7): 1737-1738.
  • 6Beuselinck B, Woher P, Karadimou A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer, 2012, 107(10): 1665-1671.
  • 7Fusco V, Porta C, Saia G, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an italian muhicenter study and review of the literature. Clin Genitourin Cancer, 2015, 13(4): 287-294.
  • 8Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase m trials in cancer patients with bone metastases. Ann Oncol, 2012, 23 (5): 1341-1347.
  • 9Van den Wyngaert T, Wouters K, Huizing MT, et ah RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer, 2011, 19( 12): 2035-2040.
  • 10Troeltzsch M, Woodlock T, Kriegelstein S, et al. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc, 2012, 78: c85.

共引文献1

同被引文献7

引证文献1

二级引证文献3

全科口腔医学电子杂志
2018年 第32期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部